Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): Updated results from a phase II trial.

被引：0
|
作者：
Shen, Bo
Wu, Yuan
Shi, Lin
Pan, Banzhou
Yang, Kaihua
Wang, Qiong
Zhao, Weiqing
Han, Zhengxiang
Wang, Lifeng
Feng, Jifeng
机构：
[1] Jiangsu Canc Hosp, Nanjing, Peoples R China
[2] Jiangnan Univ, Hosp, Wuxi, Jiangsu, Peoples R China
[3] Jiangyin Peoples Hosp, Jiangyin, Peoples R China
[4] First Peoples Hosp Changzhou, Changzhou, Jiangsu, Peoples R China
[5] Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
[6] Nanjing Univ, Drum Tower Hosp, Med Sch, Comprehens Canc Ctr, Nanjing, Peoples R China
[7] Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China
[8] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20610
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
    Gadgeel, Shirish M.
    Pennell, Nathan A.
    Fidler, Mary Jo
    Halmos, Balazs
    Bonomi, Philip
    Stevenson, James
    Schneider, Bryan
    Sukari, Ammar
    Ventimiglia, Jaclyn
    Chen, Wei
    Galasso, Cathy
    Wozniak, Antoinette
    Boerner, Julie
    Kalemkerian, Gregory P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1393 - 1399
  • [22] A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)
    Chiappori, A.
    Schreeder, M. T.
    Moezi, M. M.
    Stephenson, J.
    Blakely, J. L.
    Salgia, R.
    Chu, Q. S.
    Malik, S. M.
    Modiano, M. M.
    Berger, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] A phase II trial of carboplatin and irinotecan as first-line therapy for extensive stage small cell lung cancer (ES-SCLC): Preliminary results
    Laskin, J
    Shirley, B
    Dobbs, T
    Bi, J
    Carbone, D
    Johnson, D
    Sandler, A
    LUNG CANCER, 2005, 49 : S323 - S323
  • [24] Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer (SCLC): Final results.
    Sharma, Neelesh
    Pennell, Nathan A.
    Halmos, Balazs
    Ma, Patrick C.
    Dowlati, Afshin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.
    Chen, Dawei
    Zou, Bing
    Meng, Xiangjiao
    Huang, Wei
    Shao, Qian
    Tang, Xiaoyong
    Guo, Jun
    Hu, Xudong
    Zhang, Yan
    Fu, Lei
    Yuan Jiajia
    Yu, Jinming
    Wang, Linlin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Anlotinib Plus Etoposide and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Single Arm Phase II Trial
    Han, B.
    Zhang, W.
    Zhang, B.
    Chen, Y.
    Zhang, Y.
    Lou, Y.
    Dong, Y.
    Qian, F.
    Zhou, W.
    Yang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S503 - S503
  • [27] f Prophylactic cranial irradiation in patients with extensive-stage small-cell lung cancer (ES-SCLC): An updated tertiary cancer centre experience
    Naidoo, M.
    Lin, F.
    Jameson, M.
    Shelly, K.
    Srivastava, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 167 - 167
  • [28] Durvalumab ± tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.
    Paz-Ares, Luis G.
    Dvorkin, Mikhail
    Chen, Yuanbin
    Reinmuth, Niels
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian
    Ozguroglu, Mustafa
    Ji, Jun Ho
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Armstrong, Jon
    Byrne, Natalie
    Jiang, Haiyi
    Goldman, Jonathan Wade
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] COST OF IMMUNOTHERAPY TO TREAT EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
    Bilir, S. P.
    Ogale, S.
    VALUE IN HEALTH, 2020, 23 : S36 - S36
  • [30] Phase 2 Study Analysis of Talazoparib (TALA) Plus Temozolomide (TMZ) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Goldman, J.
    Cummings, A.
    Mendenhall, M.
    Velez, M. A.
    Babu, S.
    Johnson, T.
    Alcantar, J.
    Dakhil, S.
    Kanamori, D.
    Lawler, W.
    Anand, S.
    Chauv, J.
    Garon, E.
    Slamon, D.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S32 - S32
12345